In recent years, tumor immunotherapy has made significant progress. However, tumor
immunotherapy, particularly immune checkpoint inhibitors (eg, PD-1/PD-L1 inhibitors) …

Protein tyrosine kinases (PTKs) are a class of proteins with tyrosine kinase activity that
phosphorylate tyrosine residues of critical molecules in signaling pathways. Their basal …

Effectively activating macrophages against cancer is promising but challenging. In particular,
cancer cells express CD47, a 'don't eat me'signal that interacts with signal regulatory protein …

Immune checkpoint inhibitors (ICIs) have revolutionized the clinical management of multiple
tumours. However, only a few patients respond to ICIs, which has generated considerable …

Non-small-cell lung cancer (NSCLC) has become a paradigm of precision medicine, with
the discovery of numerous disease subtypes defined by specific oncogenic driver mutations …

Abstract The “hotness” or “coldness” of the tumors are determined by the information of the
cancer cells themselves, tumor immune characteristics, tumor microenvironment, and …

Although immune checkpoint inhibitors (ICIs) that target programmed cell death protein-
1/programmed cell death ligand-1 axis have significantly shifted the treatment paradigm in …

The advent of immunotherapy has made an indelible mark on the field of cancer therapy,
especially the application of immune checkpoint inhibitors in clinical practice. Although …

It is a challenge to effectively reactivate preexisting tumor-infiltrating lymphocytes (TILs)
without causing severe toxicity. Interleukin-12 (IL-12) can potently activate lymphocytes, but …

Abstract Programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade
has been approved as the standard-of-care for the treatment of non-small cell lung cancer …